$9.56
1.92% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US30068X1037
Symbol
XGN

Exagen Inc Stock price

$9.56
+2.49 35.22% 1M
+5.24 121.30% 6M
+5.46 133.17% YTD
+6.20 184.52% 1Y
+4.37 84.20% 3Y
-5.10 34.79% 5Y
-9.02 48.55% 10Y
-9.02 48.55% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.18 1.92%
ISIN
US30068X1037
Symbol
XGN
Industry

Key metrics

Basic
Market capitalization
$176.7m
Enterprise Value
$169.6m
Net debt
positive
Cash
$30.0m
Shares outstanding
22.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.0 | 2.7
EV/Sales
2.9 | 2.5
EV/FCF
negative
P/B
8.4
Financial Health
Equity Ratio
21.4%
Return on Equity
-158.4%
ROCE
-29.0%
ROIC
-55.9%
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
$58.9m | $66.6m
EBITDA
$-12.3m | $-5.8m
EBIT
$-14.0m | $-10.3m
Net Income
$-17.0m | $-12.6m
Free Cash Flow
$-16.0m
Growth (TTM | estimate)
Revenue
3.9% | 19.7%
EBITDA
10.9% | 51.2%
EBIT
11.2% | 24.7%
Net Income
1.9% | 16.5%
Free Cash Flow
-151.3%
Margin (TTM | estimate)
Gross
59.4%
EBITDA
-20.9% | -8.7%
EBIT
-23.9%
Net
-28.9% | -19.0%
Free Cash Flow
-27.2%
More
EPS
$-0.8
FCF per Share
$-0.7
Short interest
5.1%
Employees
212
Rev per Employee
$260.0k
Show more

Is Exagen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Exagen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Exagen Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Exagen Inc forecast:

Buy
91%
Hold
9%

Financial data from Exagen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
59 59
4% 4%
100%
- Direct Costs 24 24
3% 3%
41%
35 35
4% 4%
59%
- Selling and Administrative Expenses 43 43
3% 3%
73%
- Research and Development Expense 5.90 5.90
25% 25%
10%
-12 -12
11% 11%
-21%
- Depreciation and Amortization 1.74 1.74
13% 13%
3%
EBIT (Operating Income) EBIT -14 -14
11% 11%
-24%
Net Profit -17 -17
2% 2%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about Exagen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exagen Inc Stock News

Neutral
GlobeNewsWire
6 days ago
CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences:
Neutral
Seeking Alpha
14 days ago
Exagen Inc. (NASDAQ:XGN ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jeffrey G. Black - CFO & Corporate Secretary John Aballi - CEO, President & Director Ryan Douglas - Investors Relations Officer Conference Call Participants Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division Margarate Elizabeth Boeye - William Blair & Company L.L.C.
Neutral
The Motley Fool
14 days ago
Exagen Q2 Revenue Jumps 14 Percent
More Exagen Inc News

Company Profile

Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand. Exagen was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Head office United States
CEO John Aballi
Employees 212
Founded 2002
Website exagen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today